Alzex Neuropharma Inc. (TRRI)
| Market Cap | 602.00 -99.4% |
| Revenue (ttm) | 4.73M +6.7% |
| Net Income | 32.05K |
| EPS | n/a |
| Shares Out | 1.51M |
| PE Ratio | 0.02 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 334 |
| Open | 0.0004 |
| Previous Close | 0.0012 |
| Day's Range | 0.0004 - 0.0004 |
| 52-Week Range | 0.0001 - 0.0012 |
| Beta | -47.58 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Alzex Neuropharma
Alzex Neuropharma Inc., a development stage biopharmaceutical company, engages in developing therapeutics for the treatment of Alzheimer's Disease and other neurological diseases. The company was formerly known as Trinity Resources Inc. and changed its name to Alzex Neuropharma Inc. in December 2022. The company was incorporated in 1971 and is headquartered in Las Vegas, Nevada. [Read more]
News
Trinity Resources Inc. Awaiting Regulatory Approval of Name and Symbol Change
Las Vegas, Nevada--(Newsfile Corp. - December 16, 2022) - TRINITY RESOURCES INC. (OTC Pink: TRRI) (the "Company" or "Trinity") announces that further to its news release on August 29, 2022, it has app...
Trinity Resources Inc. Finalizes the Purchase of Alzex Biomedical Assets and Intellectual Property
-Planning a New Approach to Treat Alzheimer's Disease-Las Vegas, Nevada--(Newsfile Corp. - August 4, 2022) - TRINITY RESOURCES INC. (OTC Pink: TRRI) (the "Company" or "Trinity") is pleased to announce...